{"version":"1.0","provider_name":"Sickle Cell Disease Association of America Inc.","provider_url":"https:\/\/www.sicklecelldisease.org","author_name":"admin","author_url":"https:\/\/www.sicklecelldisease.org\/author\/admin\/","title":"ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies - Sickle Cell Disease Association of America Inc.","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"lxf4KtS57l\"><a href=\"https:\/\/www.sicklecelldisease.org\/2019\/12\/13\/ash-and-fda-unveil-new-recommendations-to-guide-clinical-development-of-sickle-cell-disease-therapies\/\">ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.sicklecelldisease.org\/2019\/12\/13\/ash-and-fda-unveil-new-recommendations-to-guide-clinical-development-of-sickle-cell-disease-therapies\/embed\/#?secret=lxf4KtS57l\" width=\"600\" height=\"338\" title=\"&#8220;ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies&#8221; &#8212; Sickle Cell Disease Association of America Inc.\" data-secret=\"lxf4KtS57l\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.sicklecelldisease.org\/wp-content\/uploads\/2019\/11\/red-blood-cells-3188223_1280.jpg","thumbnail_width":1280,"thumbnail_height":768,"description":"Joint FDA\/ASH Led Initiative Highlights Importance of Using Patient Reported Outcomes and Biomarkers in Clinical Trials to Advance SCD Therapies (WASHINGTON, DC, Dec. 6, 2019) \u2014 The American Society of Hematology (ASH) today released the most comprehensive set of recommendations to date aimed at establishing uniformity and global standards for clinical trial endpoints used to [&hellip;]"}